TCRX
TCRX
NASDAQ · Biotechnology

Tscan Therapeutics Inc

$1.01
+0.07 (+7.41%)
As of Mar 31, 10:12 PM ET ·
Financial Highlights (FY 2026)
Revenue
4.72M
Net Income
-59,284,581
Gross Margin
Profit Margin
-1,256.8%
Rev Growth
-8.6%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 59.6% 59.6%
Operating Margin -1,315.4% -1,183.8% -11.3% -9.5%
Profit Margin -1,256.8% -1,194.0% -12.6% -11.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 4.72M 5.17M 16.16M 15.23M
Gross Profit 9.63M 9.08M
Operating Income -62,079,674 -61,155,545 -1,821,663 -1,449,059
Net Income -59,284,581 -58,402,060 -2,032,977 -1,710,895
Gross Margin 59.6% 59.6%
Operating Margin -1,315.4% -1,183.8% -11.3% -9.5%
Profit Margin -1,256.8% -1,194.0% -12.6% -11.2%
Rev Growth -8.6% -8.6% -2.0% -5.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 6.12M 6.12M 15.92M 17.53M
Total Equity 23.18M 23.18M 24.83M 23.68M
D/E Ratio 0.26 0.26 0.64 0.74
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -60,737,199 -63,157,113 -2,828,117 -2,426,513
Free Cash Flow -1,769,464 -1,134,231